Navigation Links
ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
Date:1/7/2011

their performance is found to be substandard; the potential that ADVENTRX may require substantial additional funding in order to obtain FDA approval for and commercialize the TPC, and the risk that ADVENTRX may not be able to raise sufficient capital when needed, or at all; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.  

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 Pharmaceutical Care Management ... today outlined policy solutions that could reduce prescription fraud ... Hill briefing, " Prescription Opioid Abuse: Fighting Back on ... Reform and PCMA. The briefing featured ... prescription drug abuse and fraud. The Centers for Disease ...
(Date:9/29/2014)... , Sept. 29, 2014 EU5 Sigmoidoscopes ... new report, "EU5 Sigmoidoscopes Market Outlook to 2020", ... market. The report provides value, in millions of ... (in US dollars) within market segments - Flexible ... and Flexible Non-Video (Fibre) Sigmoidoscopes). The ...
(Date:9/29/2014)... SAN DIEGO , 29 de septiembre de 2014 ... adelante, Daiichi Sankyo) (TSE: 4568) y Ambit Biosciences (NASDAQ: ... que han llegado a un acuerdo de fusión definitivo ... acciones ordinarias de Ambit Biosciences a un precio de ... una oferta de licitación seguida de una fusión con ...
Breaking Medicine Technology:PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2EU5 Sigmoidoscopes Market Outlook to 2020 2EU5 Sigmoidoscopes Market Outlook to 2020 3Daiichi Sankyo adquiere Ambit Biosciences 2Daiichi Sankyo adquiere Ambit Biosciences 3Daiichi Sankyo adquiere Ambit Biosciences 4Daiichi Sankyo adquiere Ambit Biosciences 5Daiichi Sankyo adquiere Ambit Biosciences 6Daiichi Sankyo adquiere Ambit Biosciences 7Daiichi Sankyo adquiere Ambit Biosciences 8
... safety profile of BSI-201 in ... subjects with advanced solid tumors -, BRISBANE, Calif., ... developing novel cancer therapies,today announced that data supporting its lead ... of Clinical Oncology annual,meeting in Chicago., Findings will be ...
... SGP ), a leader in advancing the ... infection, announced today that data from,several clinical studies ... therapy, as well as boceprevir, the,company,s investigational oral ... annual Digestive Disease Week (DDW) meeting to be ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 ... now offering gum depigmentation treatments for dark gums. Dark ... can make people feel extremely self-conscious about their smiles. ... or dark gums. “I am one of the few ... and I have treated celebrities, business leaders, high-ranking officials ...
(Date:9/30/2014)... In books and movies, plots involving older men chasing ... suggests that the stereotype may be grounded in fact. ... than 12,000 people from Finland. The researchers, led by ... women typically preferred men who were the same age or ... On the other hand, men tended to have a lifelong ...
(Date:9/30/2014)... Sept. 30, 2014 (HealthDay News) -- For millions of ... excess weight and the threat of type 2 diabetes. ... may be tougher for some than for others, depending ... good health, it may not be as effective for ... 2 diabetes," said one expert, Dr. Ruth Loos, director ...
(Date:9/30/2014)... University of Michigan have described a new approach to ... the time needed for more traditional methods. , ... that is undergoing further investigation as a potential treatment ... , In research published online in the Proceedings ... the lab of Stephen Weiss at the U-M Life ...
(Date:9/30/2014)... Missouri (PRWEB) September 30, 2014 The ... that the SLUCare Physician Group, comprised of more than ... on a number of initiatives. With the recent ... network size, strengthening its market footprint to better respond ... Louis area. , SLPA is a physician-led clinically integrated ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:New discovery approach accelerates identification of potential cancer treatments 2Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2
... men has increased by 12% in six years, according to the ... diagnosed with the disease, 3,000 of those are men.// ... that they tend to occur more commonly on the back, whereas ... noticeable. Up to 77% of cases are caused by exposure to ...
... a mother's risk of having a hyperactive child. A ... the last three months of pregnancy had children with ... Glover, of Imperial College, London, told that this only ... frequently feeling scared.According to a survey antenatal anxiety ...
... somebody is likely to have an epileptic seizure. ,In ... warning and can lead to ,disability or even death. ... believe ,it may be possible to predict the onset ... ,An ECG records electrical activity from different parts of ...
... years. And while most of the popular remedies used in ... has increased. This powerful pill will //reduce pain, fever, inflammation, ... attacks and stroke. ,In the more than 35 ... few drugs have been developed that can even be compared ...
... one day have the option of having one blast ... up to 25 sessions afterwards, researchers said. //They believe ... for women and may improve the treatment of breast ... the developing world. ,Dr. Emiel Rutgers, of the ...
... new compounds developed for preventing and treating the flue ... only one dose to be effective.// The compounds, known ... flu drug relenza, or zanamivir, which the U.S. Food ... A and B. ,Researchers reported at the International ...
Cached Medicine News:
The 5539-7.5 linear transducer is a high frequency transducer dedicated to superficial and vascular imaging....
HST, versatile convex array abdominal transducer is multi-frequency, offering 5 levels of fundamental frequencies in addition to 4 settings of Harmonic frequencies. This transducer provides superb im...
Scan internal organs percutaneously while eliminating side lobe artifact....
... transducer is a curved ... the higher frequencies. Featuring ... this transducer provides exceptional ... frequency abdominal kidney bladder ...
Medicine Products: